ADI-212: Immune Cells Engineered to Beat Advanced Prostate Cancer

ADI-212 is a new type of immune cell therapy made from gamma delta T cells, the kind of immune cells that naturally go after tumors. These cells are specially engineered to attack PSMA-positive metastatic castration-resistant prostate cancer. The therapy has two smart upgrades. First, it carries a special version of IL-12, a powerful immune signal, […]

PSMA-1-DOTA: A New Ligand to Make Prostate Cancer Radioligand Therapy More Targeted

PSMA-targeted radioligand therapy (RLT) has transformed treatment for end-stage prostate cancer, offering strong tumor control in patients who have exhausted other options. However, these therapies frequently cause severe salivary gland damage, leading to debilitating dry mouth that often forces patients to stop treatment early. To overcome this, researchers at Case Western Reserve University developed PSMA-1-DOTA, […]

Dual FOXA1/FOXA2 Targeting to Shut Down Lineage-Plastic Castration-Resistant Prostate Cancer

Targeting FOXA1 and FOXA2 in castration-resistant prostate cancer represents a new way of attacking the disease at the level of its lineage “identity” rather than only at the androgen receptor. FOXA1 and FOXA2 belong to a family of pioneer transcription factors. These pioneer transcription factors unlock tightly packed DNA, creating access for other proteins that […]

KAIST In Situ CAR-Macrophage Therapy

The KAIST team has introduced a highly innovative form of cancer immunotherapy that turns the body’s own macrophages into potent, targeted cancer killers directly inside solid tumours. Instead of the classic, laborious route of extracting immune cells from a patient, engineering them in a lab, expanding them, and reinfusing them, this approach reprograms macrophages already […]

From T Cells to B Cells: The Next Generation of Personalized Cancer Vaccines

A research team at the Korea Advanced Institute of Science and Technology (KAIST) has developed a new artificial intelligence model that could change how personalized cancer vaccines are designed. For decades, most cancer vaccine strategies have focused on training the immune system’s T cells to attack tumors quickly and directly, which can shrink tumors but […]

CRISPR Epigenetic Editing: Safely Reactivating Genes for Sickle Cell and Cancer’s Future

A new form of CRISPR technology developed by researchers at the University of New South Wales (UNSW Sydney) and St Jude Children’s Research Hospital promises a safer path for treating genetic diseases by controlling genes without cutting DNA strands. Published in Nature Communications, the study demonstrates epigenetic editing that removes methyl groups (small chemical clusters […]

Weizmann Institute Identifies Immunotherapy Targets in Drug-Resistant Prostate Cancer

Researchers from Israel’s Weizmann Institute of Science have unveiled a promising immunotherapy strategy that targets drug-resistant cancers by exploiting the very genetic mutations responsible for treatment failure. ​ The approach centers on a computational tool called SpotNeoMet, which scans large patient datasets to identify recurrent resistance mutations that generate neo-antigens, unique protein fragments displayed exclusively […]

Immunotherapy’s Hidden Power: Reprogramming Cancer Back to Normal

In a previous article, cancer reversion was introduced as the idea that malignant cells can be pushed back toward a more normal, less aggressive state instead of simply being destroyed. That earlier discussion focused mainly on epigenetic plasticity, differentiation therapy, and microenvironmental modulation as ways to coax cancer cells into behaving more like healthy tissue. […]

Super-Adjuvant Nanoparticles: Revolutionizing Platform Cancer Vaccination

Super-adjuvant nanoparticles are a new type of cancer vaccine that works much better than older versions. Scientists at the University of Massachusetts Amherst created them. Their main study came out in October 2025 in Cell Reports Medicine. These tiny particles fight cancer by waking up the body’s immune system in a smart way. They mix […]

Frog Gut Bacterium Ewingella americana Completely Eradicates Colon Tumors in Mice

The Japanese tree frog, Dryophytes japonicus, has become the source of a striking experimental cancer approach via a gut bacterium, Ewingella americana, that can completely eradicate colorectal tumors in mice. Amphibians and reptiles rarely develop cancer, so researchers systematically screened 45 bacterial strains from frogs, newts, and lizards; nine showed anti-tumor activity, but E. americana […]